Anticuerpos antifosfolípido en población pediátrica asintomática
Antiphospholipid antibodies in asymptomatic pediatric patients
Leído
10118
Vecesse ha leído el artículo
3880
Total PDF
6238
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 8 | 11 | 19 |
| 2025 5 | 63 | 43 | 106 |
| 2025 4 | 43 | 42 | 85 |
| 2025 3 | 32 | 43 | 75 |
| 2025 2 | 85 | 51 | 136 |
| 2025 1 | 43 | 35 | 78 |
| 2024 12 | 30 | 55 | 85 |
| 2024 11 | 38 | 69 | 107 |
| 2024 10 | 38 | 68 | 106 |
| 2024 9 | 32 | 51 | 83 |
| 2024 8 | 59 | 97 | 156 |
| 2024 7 | 25 | 56 | 81 |
| 2024 6 | 44 | 51 | 95 |
| 2024 5 | 37 | 51 | 88 |
| 2024 4 | 37 | 38 | 75 |
| 2024 3 | 32 | 51 | 83 |
| 2024 2 | 40 | 67 | 107 |
| 2024 1 | 29 | 58 | 87 |
| 2023 12 | 46 | 41 | 87 |
| 2023 11 | 40 | 52 | 92 |
| 2023 10 | 37 | 50 | 87 |
| 2023 9 | 25 | 42 | 67 |
| 2023 8 | 22 | 38 | 60 |
| 2023 7 | 29 | 49 | 78 |
| 2023 6 | 30 | 43 | 73 |
| 2023 5 | 25 | 51 | 76 |
| 2023 4 | 19 | 23 | 42 |
| 2023 3 | 32 | 46 | 78 |
| 2023 2 | 14 | 16 | 30 |
| 2022 1 | 20 | 49 | 69 |
| 2022 12 | 20 | 33 | 53 |
| 2022 11 | 40 | 50 | 90 |
| 2022 10 | 26 | 46 | 72 |
| 2022 9 | 25 | 35 | 60 |
| 2022 8 | 30 | 64 | 94 |
| 2022 7 | 26 | 45 | 71 |
| 2022 6 | 23 | 48 | 71 |
| 2022 5 | 21 | 52 | 73 |
| 2022 4 | 42 | 83 | 125 |
| 2022 3 | 29 | 98 | 127 |
| 2022 2 | 18 | 56 | 74 |
| 2021 1 | 19 | 57 | 76 |
| 2021 12 | 27 | 54 | 81 |
| 2021 11 | 16 | 74 | 90 |
| 2021 10 | 43 | 66 | 109 |
| 2021 9 | 24 | 55 | 79 |
| 2021 8 | 20 | 30 | 50 |
| 2021 7 | 23 | 45 | 68 |
| 2021 6 | 21 | 40 | 61 |
| 2021 5 | 27 | 45 | 72 |
| 2021 4 | 48 | 96 | 144 |
| 2021 3 | 39 | 35 | 74 |
| 2021 2 | 38 | 41 | 79 |
| 2020 1 | 39 | 38 | 77 |
| 2020 12 | 23 | 42 | 65 |
| 2020 11 | 37 | 52 | 89 |
| 2020 10 | 14 | 32 | 46 |
| 2020 9 | 17 | 28 | 45 |
| 2020 8 | 23 | 29 | 52 |
| 2020 7 | 31 | 31 | 62 |
| 2020 6 | 22 | 22 | 44 |
| 2020 5 | 33 | 49 | 82 |
| 2020 4 | 24 | 15 | 39 |
| 2020 3 | 19 | 13 | 32 |
| 2020 2 | 21 | 26 | 47 |
| 2020 1 | 20 | 27 | 47 |
| 2019 12 | 34 | 31 | 65 |
| 2019 11 | 27 | 14 | 41 |
| 2019 10 | 19 | 17 | 36 |
| 2019 9 | 20 | 43 | 63 |
| 2019 8 | 17 | 26 | 43 |
| 2019 7 | 31 | 40 | 71 |
| 2019 6 | 26 | 49 | 75 |
| 2019 5 | 52 | 111 | 163 |
| 2019 4 | 26 | 96 | 122 |
| 2019 3 | 21 | 34 | 55 |
| 2019 2 | 22 | 13 | 35 |
| 2019 1 | 18 | 29 | 47 |
| 2018 12 | 15 | 24 | 39 |
| 2018 11 | 46 | 20 | 66 |
| 2018 10 | 43 | 15 | 58 |
| 2018 9 | 22 | 10 | 32 |
| 2018 8 | 1 | 0 | 1 |
| 2018 6 | 2 | 0 | 2 |
| 2018 5 | 4 | 0 | 4 |
| 2018 4 | 9 | 0 | 9 |
| 2018 3 | 10 | 0 | 10 |
| 2018 2 | 6 | 0 | 6 |
| 2018 1 | 7 | 0 | 7 |
| 2017 12 | 8 | 0 | 8 |
| 2017 11 | 16 | 0 | 16 |
| 2017 10 | 9 | 1 | 10 |
| 2017 9 | 10 | 0 | 10 |
| 2017 8 | 10 | 0 | 10 |
| 2017 7 | 14 | 1 | 15 |
| 2017 6 | 26 | 15 | 41 |
| 2017 5 | 27 | 7 | 34 |
| 2017 4 | 16 | 6 | 22 |
| 2017 3 | 19 | 8 | 27 |
| 2017 2 | 19 | 7 | 26 |
| 2016 1 | 9 | 4 | 13 |
| 2016 12 | 13 | 6 | 19 |
| 2016 11 | 31 | 6 | 37 |
| 2016 10 | 35 | 5 | 40 |
| 2016 9 | 33 | 8 | 41 |
| 2016 8 | 26 | 6 | 32 |
| 2016 7 | 8 | 2 | 10 |
| 2016 4 | 1 | 0 | 1 |
| 2016 3 | 6 | 0 | 6 |
| 2015 12 | 1 | 0 | 1 |
| 2015 11 | 1 | 0 | 1 |
| 2015 10 | 1 | 8 | 9 |
| 2015 8 | 4 | 11 | 15 |
| 2015 7 | 10 | 0 | 10 |
| 2015 6 | 9 | 5 | 14 |
| 2015 5 | 14 | 0 | 14 |
| 2015 4 | 15 | 6 | 21 |
| 2015 3 | 12 | 5 | 17 |
| 2015 2 | 12 | 0 | 12 |
| 2015 1 | 13 | 0 | 13 |
| 2014 12 | 19 | 0 | 19 |
| 2014 11 | 15 | 1 | 16 |
| 2014 10 | 15 | 0 | 15 |
| 2014 9 | 26 | 2 | 28 |
| 2014 8 | 28 | 1 | 29 |
| 2014 7 | 24 | 1 | 25 |
| 2014 6 | 61 | 8 | 69 |
| 2014 5 | 63 | 4 | 67 |
| 2014 4 | 49 | 1 | 50 |
| 2014 3 | 50 | 4 | 54 |
| 2014 2 | 36 | 7 | 43 |
| 2014 1 | 53 | 7 | 60 |
| 2013 12 | 44 | 8 | 52 |
| 2013 11 | 40 | 11 | 51 |
| 2013 10 | 45 | 7 | 52 |
| 2013 9 | 39 | 8 | 47 |
| 2013 8 | 42 | 12 | 54 |
| 2013 7 | 41 | 4 | 45 |
| 2013 6 | 6 | 2 | 8 |
| 2013 5 | 6 | 2 | 8 |
| 2013 4 | 9 | 0 | 9 |
| 2013 3 | 8 | 3 | 11 |
| 2013 2 | 21 | 3 | 24 |
| 2013 1 | 10 | 1 | 11 |
| 2012 12 | 9 | 1 | 10 |
| 2012 11 | 7 | 1 | 8 |
| 2012 10 | 2 | 2 | 4 |
| 2012 9 | 5 | 1 | 6 |
| 2001 4 | 2537 | 0 | 2537 |
Mostrar todo
